Llovet-Rausell Andrea, Navalón-Tortosa Jorge, Druchkiv Vasyl, Coloma-Bockos Javier, Moya-Roca Jaime, Llovet-Osuna Fernando
Clinica Baviera-AIER Eye Group, Valencia, Spain.
Chongqing Eye and Vision Care Hospital-AIER Eye Hospital Group, Valencia, Spain.
Eye Vis (Lond). 2025 Jun 16;12(1):23. doi: 10.1186/s40662-025-00439-z.
Patient expectations for post-cataract surgery outcomes have risen. This study aims to evaluate patient satisfaction after bilateral implantation of enhanced monofocal IOL (RayOne EMV RAO200E) designed with positive spherical aberration, used for monovision with a 1.00 D offset.
Prospective, non-comparative, interventional case series. Patients underwent bilateral cataract surgery and implantation of an enhanced monofocal IOL (RayOne EMV IOL RAO200E, Rayner, Worthing, UK) with target refraction of -1.00 D in the non-dominant eye and emmetropia in the dominant eye. Patient-reported outcome measures (PROMs) were assessed 3 months postoperatively using the Spanish version of the Catquest-9SF and a self-administered questionnaire. Other outcome measures included subjective refraction, visual acuity at various distances, and contrast sensitivity.
Both eyes of 51 patients were included (102 eyes). Three months postoperatively, all patients reported being satisfied or very satisfied with the overall surgical outcomes. The majority of patients reported that their vision during night driving was as good or better than before the surgery (95%); further, there was no difficulty in recognizing faces (93%), navigating uneven terrain (95%), and viewing prices while shopping (81%). The mean subjective spherical equivalent for dominant and non-dominant eyes were -0.24 ± 0.34 D and -0.86 ± 0.33 D, respectively. Binocular UDVA (4 m), UIVA (66 cm), and UNVA (40 cm) were 0.06 ± 0.09, 0.25 ± 0.12, and 0.30 ± 0.11 logMAR, respectively. Contrast sensitivity was within the population norms (CSV-1000).
Monovision with the RayOne EMV IOL provided high patient satisfaction, with preserved contrast sensitivity, good distance vision, and functional intermediate and near vision.
Clinicaltrials.gov, NCT06528678. Registered 22 July 2024-Retrospectively registered, https://clinicaltrials.gov/study/NCT06528678 .
患者对白内障手术后效果的期望有所提高。本研究旨在评估双侧植入具有正球差设计的增强型单焦点人工晶状体（RayOne EMV RAO200E）后的患者满意度，该人工晶状体用于单眼视，偏移量为1.00 D。
前瞻性、非对照、干预性病例系列研究。患者接受双侧白内障手术，并植入增强型单焦点人工晶状体（RayOne EMV人工晶状体RAO200E，Rayner，英国沃辛），非优势眼的目标屈光度为-1.00 D，优势眼为正视。术后3个月使用西班牙语版的Catquest-9SF和一份自填问卷评估患者报告的结局指标（PROMs）。其他结局指标包括主观验光、不同距离的视力和对比敏感度。
纳入51例患者的双眼（共102只眼）。术后3个月，所有患者均报告对总体手术效果满意或非常满意。大多数患者报告其夜间驾驶时的视力与手术前一样好或更好（95%）；此外，在识别面部（93%）、在不平坦地形行走（95%）以及购物时看价格（81%）方面没有困难。优势眼和非优势眼的平均主观球镜当量分别为-0.24±0.34 D和-0.86±0.33 D。双眼远距未矫正视力（4 m）、中距未矫正视力（66 cm）和近距未矫正视力（40 cm）分别为0.06±0.09、0.25±0.12和0.30±0.11 logMAR。对比敏感度在人群正常范围内（CSV-1000）。
使用RayOne EMV人工晶状体进行单眼视可使患者高度满意，保留对比敏感度，具有良好的远视力以及功能性中距和近视力。
Clinicaltrials.gov，NCT06528678。于2024年7月22日注册——追溯注册，https://clinicaltrials.gov/study/NCT06528678 。
